Meridian Bioscience (VIVO) Issues FY09, Reaffirms FY08 Outlook; Intends to Recommend Qtr. Dividend Increase
Tweet Send to a Friend
Meridian Bioscience, Inc (NASDAQ: VIVO) sees FY09 sales of $157-$160 million, versus the consensus of $159.66 million and EPS in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
